FDA OKs Roche’s Zelboraf for rare blood disease
US regulators have approved Roche’s Zelboraf (vemurafenib) for patients with a rare blood condition called Erdheim-Chester disease (ECD) carrying a mutation called BRAF V600
Read More
Tag: Zelboraf
Roche pushes Tecentriq combos into PhIII melanoma trials
Roche is planning to initiate late-stage studies investigating potential combinations for patients with advanced skin cancer based on its immunotherapy Tecentriq, which is already on the market for lung and bladder cancer.
Read More
NICE nods for Tagrisso, Cimzia and Zepatier
Cost regulators for treatments used by the NHS in England and Wales have published three sets of final guidances giving routine access to new options for lung cancer, rheumatoid arthritis and hepatitis C, and one rejecting a new therapy for melanoma.
Read More
NICE rejects Roche’s melanoma combo
Patients in England and Wales with a certain type of advanced skin cancer will not be getting routine access to Roche’s Cotellic/Zelboraf combination on the NHS, after it was turned down by the National Institute for Health and Care Excellence.
Read More
NICE rejects Roche’s Cotellic for melanoma
The National Institute for Health and Care Excellence is not backing National Health Service use of Roche’s Cotellic/Zelboraf as a treatment for melanoma.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
